Critical Reviews™ in Eukaryotic Gene Expression

The Molecular Mechanism of EPO Regulates the Angiogenesis after Cerebral Ischemia through AMPK-KLF2 Signaling Pathway

RESUMO

Objective: In this study, the molecular mechanism by which EPO regulates the angiogenesis after cerebral ischemia through AMPK-KLF2 signaling pathway was investigated. Methods: Sixty healthy, male, C57BL/6 mice were randomly divided into three groups of 20 mice: a sham group, the middle cerebral artery occlusion (MCAO) group, and a MCAO+EPO treatment group. The MCAO model was established using a modified ZeaLonga method. Mice in the EPO treatment group were injected with EPO immediately after reperfusion (5000 IU/kg), and EPO was injected the following day. The number of mouse deaths and neurologic function scores were recorded during the experiment. On day 7 after cerebral ischemia, brain tissue proteins were extracted. The following proteins expressions were detected by western blot assay: EPO, vascular endothelial growth factor (VEGE), vascular endothelial growth factor receptor (KDR), adenosine activated protein kinase (AMPK), and alpha HIF-1α alpha (HIF-1α), KLF2 and nitric oxide synthase (eNOS). Results: Compared with the MCAO group, the survival rate of mice in the EPO group was significantly improved and neurological function was significantly improved (P < 0.01). Western blot results showed that the content of EPO in brain tissue in MCAO group significantly increased compared with sham group. The content of EPO in the brain tissue of mice in the MCAO+EPO treatment group was significantly higher than in that of the MCAO group, which indicates that EPO increased the content of EPO in mouse brain tissue. Compared with the sham group, the protein expression of vascular endothelial growth factor (VEGE) and its receptor (KDR) in brain tissue of the MCAO group significantly decreased. However, the protein expression of VEGE and its receptor KDR in brain tissue of rats treated with MCAO+EPO was significantly higher than in that of the MCAO group. Thus, in this study, EPO was associated with vascular endothelial differentiation after cerebral ischemia in mice. The results of AMPK and KLF2 showed that the expression levels of AMPK and KLF2 in brain tissues of MCAO group mice significantly decreased compared with the sham group. However, the expression levels of AMPK and KLF2 in brain tissues of mice treated with MCAO+EPO were significantly higher than those in the MCAO group. Thus, EPO can activate AMPK and upregulate the expression of the transcription factor KLF2. The protein expression of HIF-1α in the brain tissue of mice in the MCAO group significantly increased compared with the sham group. However, the expression of HIF-1α in mice brain tissues in the MCAO+EPO treatment group was significantly lower than in that of the MCAO group, indicating that EPO was involved in regulating HIF-1α expression. The eNOS results showed that, compared with Sham group, the protein expression of eNOS in brain tissue of MCAO group mice significantly decreased. In the MCAO+EPO treatment group, the protein expression of eNOS was significantly higher in the brain tissue of the mice than in that of the MCAO group, indicating that EPO was involved in the synthesis of NO and promoted the angiogenesis. Conclusion: EPO promotes VEGE and its receptor (KDR) expression and participates in the regulation of HIF-1α and eNOS protein expression through the activation of AMPK-KLF2 signaling pathways to promote new vascular development after cerebral ischemia.

Referências

1. Almaguer-Melian W, Merceron-Martinez D, Delgado-Ocana S, Pavon-Fuentes N, Ledon N, Bergado JA. , EPO induces changes in synaptic transmission and plasticity in the dentate gyrus of rats. Synapse. 2016;70:240–52.

2. Li X, Chen Y, Shao S, Tang Q, Chen W, Chen Y, Xu X. , Oxidative stress induces the decline of brain EPO expression in aging rats. Exper Gerontol. 2016;83:89–93.

3. Kiss K, Csonka C, Paloczi J, Pipis J, Gorbe A, Kocsis GF, Murlasits Z, Sarkozy M, Szucs G, Holmes CP, Pan Y, Bhandari A, Csont T, Shamloo M, Woodburn KW, Ferdinandy P, Bencsik P. Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats. Pharma Res. 2016;113:62–70.

4. Funakoshi-Tago M, Moriwaki T, Ueda F, Tamura H, Kasahara T, Tago K. , Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR. Cell Signal. 2017;31:41–57.

5. Ackerson JP, Morgan CLS, Ge Y. , Penetrometer-mounted VisNIR spectroscopy: application of EPO-PLS to in situ VisNIR spectra. Geoderma. 2017;286:131–38.

6. Neuberger EW, Perez I, Le Guiner C, Moser D, Ehlert T, Allais M, Moullier P, Simon P, Snyder RO. , Establishment of two quantitative nested qPCR assays targeting the human EPO transgene. Gene Ther. 2016;23:330–9.

7. Kim AR, Ulirsch JC, Wilmes S, Unal E, Moraga I, Karakukcu M, Yuan D, Kazerounian S, Abdulhay NJ, King DS, Gupta N, Gabriel SB, Lander ES, Patiroglu T, Ozcan A, Ozdemir MA, Garcia KC, Piehler J, Gazda HT, Klein DE, Sankaran VG, Functional selectivity in cytokine signaling revealed through a pathogenic EPO mutation. Cell. 2017;168:1053–64.

8. Carelli S, Giallongo T, Viaggi C, Latorre E, Gombalova Z, Raspa A, Mazza M, Vaglini F, Di Giulio AM, Gorio A. , Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors. Neuropharmacology. 2017;119:76–90.

9. Heitrich M, Garcia DM, Stoyanoff TR, Rodriguez JP, Todaro JS, Aguirre MV, Erythropoietin attenuates renal and pulmonary injury in polymicrobial induced-sepsis through EPO-R, VEGF and VEGF-R2 modulation. Biomed Pharmacother. 2016;82:606–13.

10. Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander E, Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: an analysis from the EPOC (Evaluate Patient OutComes) trial. J Neuro Sci. 2016;365:190–98.

11. Rao E, Zhang Y, Li Q, Hao J, Egilmez NK, Suttles J, Li B. , AMPK-dependent and independent effects of AICAR and compound C on T-cell responses. Oncotarget. 2016;7:33783–95.

12. Desantis V, Frassanito MA, Tamma R, Saltarella I, Di Marzo L, Lamanuzzi A, Solimando AG, Ruggieri S, Annese T, Nico B, Vacca A, Ribatti D. , Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma. Annals Hematol.2018;97:1251–58.

13. Kosinski P, Bomba-Opon DA, Wielgos M., First trimester erythropoietin (EPO) serum concentration as a potential marker for abnormal placentation disorders. Reference values for erythropoietin (EPO) concentration at 11-13(+)(6) weeks of gestation. J Perinatal Med. 2016;44:187–93.

14. Wang D, Song Y, Zhang J, Pang W, Wang X, Zhu Y, Li X. , AMPK-KLF2 signaling pathway mediates the proangiogenic effect of erythropoietin in endothelial colony-forming cells. Am J Physiol Cell Physiol. 2017;313:C674–C85.

15. Boss M, Newbatt Y, Gupta S, Collins I, Brune B, Namgaladze D. , AMPK-independent inhibition of human macrophage ER stress response by AICAR. Sci Rep. 2016;6:32111.

16. Walter C, Clemens LE, Müller AJ, Fallier-Becker P, Proikas-Cezanne T, Riess O, Metzger S, Nguyen HP., Activation of AMPK-induced autophagy ameliorates Huntington disease pathology invitro. Neuropharmacology. 2016;108:24–38.

17. Gao M, Kong Q, Hua H, Yin Y, Wang J, Luo T, Jiang Y. , AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin. Oncotarget. 2016;7:16349–61.

18. Jin Y, Liu S, Ma Q, Xiao D, Chen L. , Berberine enhances the AMPK activation and autophagy and mitigates high glucose-induced apoptosis of mouse podocytes. Eur J Pharmacol. 2017;794:106–14.

19. Wang YG, Qu XH, Yang Y, Han XG, Wang L, Qiao H, Fan QM, Tang TT, Dai KR. , AMPK promotes osteogenesis and inhibits adipogenesis through AMPK-Gfi1-OPN axis. Cell Signal. 2016;28:1270–82.